Protox Announces New Director of Investor Relations and Corporate Communications
Vancouver, British Columbia, August 24, 2006 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced that Anthony Boone will join the company as Director of Investor Relations and Corporate Communications. Mr. Boone brings over fifteen years of senior corporate communications experience to the position including ten years with IMS Health Canada, a subsidiary of IMS Health the world's largest provider of information and analysis to the pharmaceutical industry. At IMS he directed the company's corporate communications activities, including marketing communications, stakeholder relations, media relations and crisis communications. During this tenure he also served on the company's Senior Management Committee and the Global Communications Team.
“We are extremely pleased to have Anthony join our team here at Protox,” said Dr. Fahar Merchant, President and Chief Executive Officer of Protox Therapeutics. “His strong communications expertise will be invaluable in disseminating news and developments to our key stakeholders as our expanded clinical programs continue to make progress.”
Mr. Boone's background also includes pharmaceutical market research and communications consulting for a number of life science companies, including QLT, AnorMED and Johnson & Johnson LifeScan. His annual report work has won the prestigious Mead and AR100 awards. Most recently he was Senior Communications Advisor with CGA-Canada. His educational background includes a bachelor's degree in commerce from Carleton University.
About Protox
Protox Therapeutics is a product-focused company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company currently has three clinical programs in various stages of development for the treatment of primary brain cancers, localized prostate cancer and cancers that over-express IL-4 receptors. The company also has a pre-clinical program for benign prostatic hyperplasia (BPH) that is expected to enter clinical trials. Through the company's INxin™ and PORxin™ technology platforms, therapeutic candidates are generated by engineering naturally occurring toxins. These drugs are potent anti-cancer agents with distinct modes of action. INxin drugs target cancer cells that produce specific tumor associated receptors on their cell surface. Once bound to the cancer cells, INxin drugs enter the cell and inhibit protein synthesis which ultimately leads to cell death. PORxin drugs are pro-drugs that are activated by specific proteases produced at elevated levels by target cells. Once activated, the drug punches holes in the cells causing the contents to leak out and ultimately cell death.
NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information contact:
Anthony Boone
Director, Investor Relations and Corporate Communications
Protox Therapeutics Inc.
604-688-0199
aboone@protoxtherapeutics.com
Michael Moore
Investor Relations
The Equicom Group
416-815-0700 x 241
mmoore@equicomgroup.com